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in South Africa where dideoxynucleosides are used as nucle-
oside backbones for HAART in the public sector. This study
reviews the incidence, characteristics, analysis frequently
reported symptoms and documents outcomes of SHL and LA.
Method: Retrospective cohort analysis was performed
of 1175 adults (66.5% female) who started on ART from
January 2004 to January 2007 at the Tygerberg Hospital
Infectious Diseases Clinic. All patients with two lactate lev-
els of >2,5mmol/l and symptoms compatible with SHL during
the study period were included in the analysis.
Results: A total of 79 patients presented with SHL (65
female). The overall incidence was 42 cases per 1000
patient- years. The incidence among female patients was
36.1 cases per 1000 p-y compared to 6.1 cases per 1000 p-y
on treatment among male patients. 46 patients (58%) had
lactate measurements of >5mmol/l giving it and incidence
of 22 cases per 1000 p-y. Two patients (2, 5%) died. Median
age was 37 years, median baseline CD4 102 and median dura-
tion of ART was 11 months. The baseline median BMI was 24,
1. Seventeen (23, 6%) of 72 patients with SHL were obese
(BMI > 30). All 79 patients were on d4T prior to develop-
ing SHL. Most frequently reported symptoms were weight
loss (61%), nausea and vomiting 58%, abdominal pain or ten-
derness 55% and peripheral neuropathy occurred in 51% of
patients. Of the 70 patients restarted or continued with AZT
only 1 patient developed a recurrence.
Conclusion: A higher incidence was found as the cohort
included the entire spectrum of SHL. The frequency of SHL
was higher among women. The low mortality in this cohort
is likely due to increased awareness of clinicians and due
to inclusion of mild to moderate forms of SHL. AZT seems
a safe alternative where NRTI options are limited. These
ﬁndings mirror results found in other South African cohort
in the public sector ARV roll-out program.
doi:10.1016/j.ijid.2008.05.498
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The Government of Tanzania launched ARV programme
for PLHA since 2003, with the aim of decrease suppression
of HIV replication, improve patient’s survival and to reduce
morbidity. At Ligula hospital in Mtwara Municipal where this
study was conducted, the programme was introduced in
June 2005. This dissertation attempts to describe a study
conducted to identify the factors contributing to ARV non-
adherence among PLHA attending CTC at Ligula hospital.
This study was under taken during October 2006 with 50
respondents who included 45 ARV users and ﬁve (5) service
providers. The respondents were selected by using simple
random sampling method. Data was collected by using a
semi-structured questionnaire, and then data analysis was
done manually.
Majority (60%) of respondents reported to have had failed
to adhere to prescribed regimen. The reasons for non-
adherence included; 55% lack of privacy, 44.4% long distance
to hospital, 44.4% out of their home and 41% simply forgot
33.3% don’t want to be notice, 25% alternative therapy, 15%
side effect of drug. When reporting about non-adherence,
the interviewed service providers mentioned the use of tra-
ditional medicine 80%, low capacity of client to understand
80% economic constraints 60%, lack of support 40%, long
distance to clinic 20%, side effect 20%, and feels recovery
20%.
This study concludes that, factors for ARV’s non-
adherence are multi-factorial. These results are useful in
planning interventions to promote medication adherence
among clients receiving ARV at Ligula hospital and similar
settings. Both clients and providers should be targeted by
interventions aimed at improving adherence to ARVs.
doi:10.1016/j.ijid.2008.05.499
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Background: Due to limited regimen options in resource-
limited settings, it is important to maximize the durability of
response to ﬁrst-line antiretroviral therapy in order to opti-
mize patient outcomes and maintain lower program costs.
Objectives: To conduct a pilot study of initiation of a one-
month period of directly administered antiretroviral therapy
(DAART) for participants with suspected ﬁrst-line treatment
failure. The primary outcome was the change in CD4 lym-
phocyte count following DAART.
Methods: We conducted a prospective cohort study in
Mombasa, Kenya between 2004 and 2007. We identiﬁed all
women on ART who met WHO criteria for immunological
treatment failure but were clinically stable. These women
received four weeks of DAART, during which we directly
administered the morning dose at the clinic for ﬁve days
each week.
Results: Fourteen women resumed DAART. The median
time to suspected treatment failure was 428 days (interquar-
tile range [IQR], 333—819 days), and the median CD4 cell
count at treatment failure was 152 cells/microliter (IQR,
112—232). Following one month of DAART, 5 women were
diagnosed with treatment failure, while 9 women were
no longer classiﬁed as failing. Among those who failed,
the median CD4 counts were 153 cells/microliter (IQR, 63-
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222) before, and 153 cells/microliter (IQR, 49—187; p = 0.3)
after DAART. Among those who no longer met the treat-
ment failure criteria after DAART, the median CD4 counts
were 150 cells/microliter (IQR, 113-233) before, and 244
cells/microliter (IQR, 132—287; p = 0.02) after DAART. At
the time of this analysis, the women who responded to
DAART have remained on ﬁrst-line therapy without addi-
tional episodes of treatment failure for amedian of 170 (IQR,
57—450) days.
Conclusions: One month of DAART with adherence coun-
seling could provide a simple, low-cost method of optimizing
the durability of response to ﬁrst-line ART and distinguishing
faltering adherence from treatment failure.
doi:10.1016/j.ijid.2008.05.500
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Background: The 1994 International Conference on Pop-
ulation and Development in Cairo, Egypt drew attention to
comprehensive reproductive health for women. The central
role of reproduction in the lives of women in many parts
of the world is now recognized. We assessed the frequency
of reproductive-organ disease in a cohort of HIV-positive
women with a view to determine the effect of HAART on
their frequency of occurrence.
Methods: 369 HIV-positive women aged between 15
to 64 years were recruited. Demographic data, history
of reproductive organ disease and use of HAART were
obtained. Pelvic examination was carried and Pap smears
were obtained for cytology.
Results: The mean age for those on HAART was 34.8± 7.3
and 33.4± 7.3 years for the HAART naive group (p = 0.08).
Mean duration of HAART use was 14.7± 11.5 months. Fre-
quency of reproductive-organ symptoms and examination
ﬁndings between the two groups (no HAART vs HAART)
are as follows; amenorrhea −80.7% vs 22.0% (p 0.001),
vaginal discharge −83.3% vs 16.7 (p 0.01), vaginal itching
−84.0% vs 16.0% (p < 0.001), irregular menses −81.7% vs
18.3% (p < 0.001), post-coital bleeding -86.7% vs 13.3% (p
0.06), history of previous STI −66.5% vs 33.5% (p 0.34), lower
abdominal pain −77.6% vs 22.4% (p 0.12), genital warts
−73.3% vs 26.7% (p 0.51), genital ulcers −68.5% vs 31.5% (p
0.91), cervical motion tenderness −87.0% vs 13.0% (p 0.05),
contact bleeding −76.2% vs 23.8% (p 0.05), abnormal cytol-
ogy −69.4% vs 30.6% (p 0.83), other abnormal lesions −73.2%
vs 26.8% (p 0.19).
Conclusion: This study revealed a higher frequency of
reproductive-organ disease in HIV-positive women who are
HAART na¨ıve compared with those on HAART. Treating HIV-
infection therefore has additional sex-speciﬁc beneﬁts for
women in terms of reproductive health morbidity, and
widespread access to treatment with integration of repro-
ductive health services should be advocated.
doi:10.1016/j.ijid.2008.05.501
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Objectives: A proportion of HIV patients beginning
antiretroviral therapy (ART) develop immune restoration
disease (IRD). Longitudinal changes in plasma antibody titer
were investigated in relation to IRD in a cohort of HIV
patients beginning therapy with a range of opportunistic
infections.
Design: Plasma were collected from 20 male (16 Chinese
and 4 Malay) HIV patients beginning ART with <100 CD4 T-
cells/l at the University of Malaya Medical Centre, Kuala
Lumpur, on 5 occasions over the ﬁrst year of therapy. 10
patients experienced IRD [3 with suspected cytomegalovirus
(CMV) disease, 2 with cryptococcal disease, 4 with tubercu-
losis (TB) and 1 with varicella zoster virus (VZV)].
Methods: Plasma antibodies (IgG) reactive with CMV,
Cryptococcal, PPD and VZV antigens were assessed using
standard ELISA method.
Results: All patients showed high level of anti-CMV anti-
body during 12 months on ART, regardless of IRD. Antibody
reactive to cryptococcal antigen peaked only at the time of
cryptococcal IRD. Anti-PPD titers were elevated at the start
of ART in two TB IRD patients and remained high or increased
further at the time of their IRD. However, the other two
TB IRD patients retained intermediate titers throughout ﬁrst
year of ART. Anti-VZV titers were detectable in the VZV IRD
patient at the start of ART, with a marginal increment during
IRD.
Conclusions: Despite their immunodeﬁciency, HIV-
infected patients display restored antigen-speciﬁc IgG
antibody responses during 12 months of ART. The high titer
of anti-CMV IgG in most patients regardless of IRD may
reﬂect the reactivation of CMV by chronic immune activa-
tion. Generally, antibody titers were extremely variable
among cohort participants but relatively stable over time,
suggesting inherent differences in immune capacity.
doi:10.1016/j.ijid.2008.05.502
